原文链接:https://link.springer.com/article/10.1186/s12951-024-03072-5?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20241223&utm_content=10.1186/s12951-024-03072-5#Sec27
^Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024 May;20(5):261-277. doi: 10.1038/s41574-023-00943-z. Epub 2024 Feb 6. PMID: 38321142. ^https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 ^...
即便在F1-F3期NASH有效,但司美和其他药物都未展现在F4(肝硬化阶段)NASH上有确切10疗效。 OSA(呼吸阻塞性睡眠)、 OA (膝关节骨关节炎):肥胖且伴随OSA、OA的患者有望受益 礼来的替尔泊肽于2023.10月完成“肥胖患者中不能或不愿使用呼吸机治疗”的3期临床患者入组,预期2024H1将...
[2] Wharton, Sean et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” The New England journal of medicine vol. 389,10 (2023): 877-888. doi:10.1056/NEJMoa2302392 [3] Wilding, John P H et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesi...
New New England Journal of Medicine, 2021. https://doi.org/10.1056/NEJMoa2107519. [6] Newsome, P.N., K. Buchholtz, K. Cusi, M. Linder, T. Okanoue, V. Ratziu, et al.,A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepa- titis. ...
5.https://doi.org/10.1056/NEJMoa2107519 6.Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist.doi.org/10.1016/j.hsr.2022.100032 7.How May GIP Enhance the Therapeutic Efficacy of GLP-1?https://doi.org/10.1016/j.tem.2020.02.006 8.Perspectives...
本次登记的两项 III 期临床试验,TRIUMPH-1 针对肥胖症/超重,纳入患者亚组包括膝关节炎(OA)、睡眠呼吸阻塞(OSA)亚组;TRIUMPH-2 针对肥胖/超重的 2 型糖尿病患者,同样包含 OSA 亚组。前者预计入组 2100 例,后者预计入组 1000 例,两项试验开展地区都包含中国。
图3:于2023年6月23日发表于NEJM上,DOI: 10.1056/NEJMoa2302392 这些肥胖治疗的药物分别是来自Novo Nordisk(诺和诺德)的semaglutide(司美格鲁肽,口服制剂),来自Eli Lilly(礼来)的retatrutide(针剂)和orforglipron(口服制剂)。前者是去年卖断货的大名鼎鼎的“减肥针”——司美格鲁肽的口服剂型;后两者是即将在未来几...
#被滥用的减肥神药#所谓减肥针主要是GLP-1受体激动剂,是通过延缓胃排空,提升饱感,降低食欲来减少食物的。但它也可能导致胃肠道不适和营养不良,并不适合那些原本消化能力差、肌肉少、食量小的人,也不适合有甲状腺疾病、胃肠疾病、肝胆疾病、胰腺疾病的人。这类处方药在我国尚未按减肥药获得审批,没有医学评估和处方...
2. Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.N Engl J Med. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392 3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor...